Arrowhead Pharmaceuticals, Inc.
ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial toā¦ read more
Healthcare
Biotechnology
32 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$65.91
Price-0.73%
-$0.48
1Y
Price
Market Cap
$9.112b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-534.7%
EBITDA Margin-631.1%
Net Profit Margin-565.7%
Free Cash Flow Margin-534.7%
EBITDA Margin-631.1%
Net Profit Margin-565.7%
Free Cash Flow MarginRevenue
$596.565m
+16699.9%
1y CAGR+5533.5%
3y CAGR+4169.1%
5y CAGREarnings
-$148.417m
+75.2%
1y CAGR-44.5%
3y CAGR-39.6%
5y CAGREPS
-$1.30
+74.0%
1y CAGR-33.8%
3y CAGR-31.0%
5y CAGRBook Value
$519.806m
$1.381b
Assets$860.806m
Liabilities$713.286m
DebtDebt to Assets
51.7%
-13.6x
Debt to EBITDAFree Cash Flow
-$17.621m
+97.1%
1y CAGR-20.2%
3y CAGR-72.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company